 |
|
Progression of Occlusive AtherosclerosisLong-Term Administration of Pyridinol Carbamate
Walter Redisch, MD;
Roy H. Clauss, MD;
Lawrence R. Rouen;
Monique C. Katz, MD;
Erwin N. Terry, MD
Arch Surg. 1975;110(3):258-261.
Abstract
The effects of pyridinol carbamate, a drug with demonstrated capacity to inhibit development of atherosclerotic plaques in the rabbit, were studied in humans with symptoms of arterial occlusive disease in the lower extremities. Microcirculation, perfusion, claudication distance, peripheral pulsations, and angiographic appearances were supplemented by clinical impressions over a two-year period. Although the drug was discontinued in several patients from a larger group because of gastrointestinal tract symptoms, and for other reasons, seven of eight patients receiving it showed no progression of their disease, whereas all 15 patients receiving identical-appearing placebos did. Although the number of patients is not sufficient to warrant statistical conclusions, the observations were totally objective and strongly encourage further control studies.
Author Affiliations
From the departments of medicine (Dr. Redisch), surgery (Drs. Clauss and Terry and Mr. Rouen), and radiology (Dr. Katz), New York Medical College, New York.
Footnotes
Accepted for publication Sept 13, 1974.
Reprint requests to Department of Surgery, New York Medical College, Flower and Fifth Avenue Hospitals, Fifth Avenue at 106th, New York, NY 10029 (Dr. Clauss).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Multiclinic Double-Blind Trial of Pyridinolcarbamate and Inositol Niacinate in Ischemic Ulcer Due To Chronic Arterial Occlusion
Mishima et al.
ANGIOLOGY 1977;28:84-94.
ABSTRACT
|
